Compare TSQ & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSQ | ADVM |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.8M | 94.6M |
| IPO Year | 2000 | 2014 |
| Metric | TSQ | ADVM |
|---|---|---|
| Price | $5.34 | $4.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $12.50 | $11.60 |
| AVG Volume (30 Days) | 85.0K | ★ 497.5K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | ★ 15.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $438,695,000.00 | N/A |
| Revenue This Year | N/A | $1,192.00 |
| Revenue Next Year | $1.59 | N/A |
| P/E Ratio | $4.65 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.30 | $1.78 |
| 52 Week High | $10.39 | $6.12 |
| Indicator | TSQ | ADVM |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 58.20 |
| Support Level | $4.75 | $4.15 |
| Resistance Level | $4.98 | $4.23 |
| Average True Range (ATR) | 0.22 | 0.09 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 89.00 | 95.22 |
Townsquare Media Inc is a radio, digital media, entertainment, and digital marketing solutions company principally focused on being the premier local advertising and marketing solutions platform in small and mid-sized markets across the United States. It has three segments which are Subscription Digital Marketing Solutions, Digital Advertising, and Broadcast Advertising. It earns the majority of the revenue from the Broadcasting Advertising segment, which includes its local, regional, and national advertising products and solutions delivered via terrestrial radio broadcast. Its portfolio includes local media brands such as WYRK.com, WJON.com, and NJ101.5.com, and premier national music brands such as XXLmag.com, TasteofCountry.com, UltimateClassicRock.com, and Loudwire.com.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.